nanobody-based biepitope BCMA-targeting CAR-T cells

Nanobody-based biepitope BCMA-targeting CAR-T cells represent an advanced form of chimeric antigen receptor (CAR) T-cell therapy designed to treat hematological malignancies, primarily relapsed/refractory multiple myeloma (R/RMM). This therapy involves genetically engineering a patient's own T-cells to express a CAR that specifically recognizes and binds to the B-cell maturation antigen (BCMA) found on myeloma cells. A key feature of this construct is its 'biepitopic' design, utilizing nanobodies—small, single-domain antibody fragments derived from camelid heavy-chain antibodies—to target two distinct epitopes on the BCMA protein. This dual-epitope recognition is intended to enhance binding affinity, improve tumor cell killing efficacy, and potentially overcome mechanisms of antigen escape that can lead to relapse with single-epitope targeting CAR-T therapies. The CAR typically incorporates a 4-1BB co-stimulatory domain and a CD3ζ signaling domain to promote T-cell activation, proliferation, and persistence. The therapy is administered via intravenous infusion.

Other names

biepitopic nanobody-based BCMA CAR-T construct